Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot evaluation of therapeutic drug monitoring (TDM).

Trial Profile

Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot evaluation of therapeutic drug monitoring (TDM).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Jan 2014

At a glance

  • Drugs Ritonavir (Primary) ; Tipranavir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms TICINO
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jun 2012 Additional location (Portugal) added and official title amended as reported by European Clinical Trials Database.
    • 28 Nov 2008 Actual patient number reported as 11; actual end date reported as October 2008 by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top